Identification of clinical features associated with mortality in COVID-19 patients

Rahimeh Eskandarian¹, Zahra Alizadeh Sani², Mohaddeseh Behjati³, Mehrdad Zahmatkesh¹, Azadeh Haddadi⁴, Kourosh Kakhi⁵, Mohamad Roshanzamir⁶, Afshin Shoeibi^{7,8}, Roohallah Alizadehsani^{9,*}, Sadiq Hussain¹⁰, Fahime Khozeimeh⁹, Vahideh Keyvani¹¹, Abbas Khosravi⁹, Saeid Nahavandi⁹, Sheikh Mohammed Shariful Islam^{12,13,14}

¹Internal Medicine Research Center, Semnan University of Medical Sciences, Semnan, Iran

²Omid hospital, Iran University of Medical Sciences, Tehran, Iran

³Rajaei Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran

⁴Department of Biology, Faculty of Basic Sciences, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran.

⁵Computer department, Monash University, Melbourne, Australia

⁶Department of Engineering, Fasa Branch, Islamic Azad University, Post Box No 364, Fasa, Fars 7461789818, Iran

⁷Computer Engineering Department, Ferdowsi University of Mashhad, Mashhad, Iran.

⁸Faculty of Electrical and Computer Engineering, Biomedical Data Acquisition Lab, K. N. Toosi University of Technology, Tehran, Iran.

⁹Institute for Intelligent Systems Research and Innovation (IISRI), Deakin University, Victoria, Australia

¹⁰System Administrator, Dibrugarh University, Assam 786004, India

¹¹Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran.

¹²Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, VIC, 3220, Australia

¹³Cardiovascular Division, The George Institute for Global Health, Newtown, Australia

¹⁴Sydney Medical School, University of Sydney, Camperdown, Australia

* Correspondence Dr. Roohallah Alizadehsani, Email: ralizadehsani@deakin.edu.au

Summary

Background To prevent infectious diseases, it is necessary to understand how they are spread and their clinical features. Early identification of risk factors and clinical features is needed to identify critically ill patients, provide suitable treatments, and prevent mortality.

Methods We conducted a prospective study on COVID-19 patients referred to a tertiary hospital in Iran between March and November 2020. Of the 3008 patients (mean age 59.3±18.7 years, range 1 to 100 years), 1324 were women. We investigated COVID-19 related mortality and its association with clinical features including headache, chest pain, symptoms on CT, hospitalization, time to infection, history of neurological disorders, having a single or multiple risk factors, fever, myalgia, dizziness, seizure, abdominal pain, nausea, vomiting, diarrhoea and anorexia.

Findings There was a significant association between COVID-19 mortality and old age, headache, chest pain, respiratory distress, low respiratory rate, oxygen saturation less than 93%, need for a mechanical ventilator, having symptoms on CT, hospitalization, time to infection, history of hypertension, neurological disorders, cardiovascular diseases and having a risk factor or multiple risk factors. In contrast, there was no significant association between mortality and gender, fever, myalgia, dizziness, seizure, abdominal pain, nausea, vomiting, diarrhoea and anorexia.

Interpretation Our results might help identify early symptoms related to COVID-19 and better manage patients clinically.

KEYWORDS: COVID-19, mortality, risk factors, symptoms.

1. Introduction

In January 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was discovered [1]. Since then, the virus has spread exponentially and caused immense human sufferings worldwide [2-4]. The high number of deaths and the global spread of coronavirus disease (COVID-19) led the World Health Organization to announce it as a pandemic on 12 March 2020. The world has suffered a high toll from this pandemic regarding increased poverty, economic repercussions and human lives lost to date. A considerable portion of the population being asymptomatic carriers for COVID-19. Fever (83%), cough (82%) and shortness of breath (31%) are reported as the most common symptoms [5]. Chest X-ray generally demonstrates ground-glass opacity and multiple mottling in patients with pneumonia. COVID-19 patients typically yield decreased eosinophils and lymphocyte counts, lower median haemoglobin values, and enhance neutrophil counts, WBC and serum levels of ALT, AST, LDH and CRP [6]. For severe COVID-19

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Research in context

Evidence before this study

To prevent infectious diseases, it is necessary to understand how they are spread and their clinical features. Early identification of risk factors and clinical features is needed to identify critically ill patients, provide suitable treatments, and prevent mortality. As the best of our knowledge, a few researchers focused in investigation of important factors of mortality rate in COVID-19. Consequently, a few features have been investigated precisely.

Added value of this study

As far as we know, there is a few papers published in this field. In this research, the influence of different factors in COVID-19 patient's death were investigated. In addition, there are some features which we investigated for the first time.

Implications of all the available evidence

Findings these factors could help physicians to better setting the priority of treatments for patients. It results to death rate reduction. By identifying patients at risk, physicians can ascertain those who might benefit from early monitoring.

development, initial CRP serum levels have been considered an independent predictor [7]. Although the lung is the main target of COVID-19 infection, the widespread distribution of ACE2 receptors in organs [8] may lead to gastrointestinal, liver, kidney, central nervous system, cardiovascular and ocular damage needs to be closely observed [9]. Patients with acute respiratory distress syndrome may deteriorate speedily and die of multiple organ failure [5] induced by the so-called "cytokine storm". The severity of COVID-19 is also associated with elevation of D-dimer levels. The elevated D-dimer levels may reflect the risk of disseminated coagulopathy in patients with severe COVID-19, which may require anticoagulant therapy [10].

Early surveillance, contact tracing, testing, and strict quarantine are the strategies of the countries that had maintained a low COVID-19 mortality rate [11, 12]. Such countries had adopted digital technology to implement effective strategies and integrating them with healthcare. Pandemic plans are thorny to achieve manually but can be facilitated using digital health technology. Early flattening of the incidence curve was possible for some countries like South Korea, which had integrated government-coordinated mitigation and containment processes into digital technology [13]. The tracking of COVID-19 had initiated AI dashboards that showcased the disease burden. UpCodeto utilizes the data generated by the Singapore Ministry of Health to portray infection trends and recovery time [14]. The web-based platform HealthMap and COVID-19 dashboard of the Johns Hopkins University provide an up-to-date scenario of COVID-19 deaths and cases across the world [15]. AI algorithms play a vital role in the integration of digital technology with healthcare. But AI algorithms have constraints as they require a large amount of data to provide accurate results [16]. Most of the predictive COVID-19 models were based on Chinese data; hence it might not help other parts of the world. Social media and other online traffic and the absence of historical training data created noise in big datasets and produced overfitted models. These noises must be filtered to discern accurate predictions and trends. To study the risk factors, characteristics, and clinical outcome associated with COVID-19 mortality and other important factors.

Shi et al. [17] analysed the characteristics, risk factors and outcomes for in-hospital mortality of COVID-19 patients with diabetes. They abstracted laboratory, clinical, and demographic data of the patients and the risk factors associated with mortality were identified by performing Multivariable Cox regression analyses. The outcomes of COVID-19 patients with diabetes were lower than age- and sex-matched patients without diabetes.

Ji, et al. [18] exploited the association between healthcare resource availability and COVID-19 mortality. The comprehensive analysis of data from China showcased substantial disparities in mortality rates among various regions of Hubei (about 2.9% on average), Wuhan (>3%), and across the other provinces of China (on average about 0.7%). The empirical results demonstrated a striking positive correlation yielding healthcare burden was correlated with mortality. The coastal provinces of China, like Guangdong and

Zhejiane, were low mortality rates despite having a high number of patients proved the point. Li et al. [19] evaluated the severity of the admission of treatment, complications and outcomes of patients with COVID-19. A multivariable binary logistic model was devised to analyse the vital risk factors for severe COVID-19 patients. They observed that severe male patients with hyperglycemia, heart injury, and high-dose corticosteroid use might risk mortality higher.

Selenium (Se) is a crucial trace element for human health and needed for a balanced immune response. The authors [20] hypothesized that Se status was correlated with the death of COVID-19 patients. They showed that Se status was considerably lower in samples from non-survivors as compared to surviving COVID patients. Hence, the role of Se for COVID-19 patients was strengthened by their findings. Qin et al. [21] carried out a retrospective study to assess the prognostic power and associations of circulating cardiac injury markers with the severe outcome of COVID-19 patients. They concluded that COVID-19 patients with elevated cardiac injury markers above the novel recognized cutoffs were associated with an elevated risk of mortality. The current reference standards showed higher prognostic cutoff values than these biomarkers.

Statins are recommended as an adjunct therapy for COVID-19 and are lipid-lowering therapeutics with favourable anti-inflammatory profiles. In [22], the dataset of 13,981 patients with COVID-19 from China was explored, out of which 1,219 received statins. Marginal structural and Cox time-varying model analyses were utilized to observe the statin use-associated lower risk of mortality. They asserted that to combat the mortality of COVID-19 patients applying statin treatment required further study and validation.

The nutrition status of COVID-19 patients is not known. Zhao et al. [23] examined critically and severely ill COVID-19 patients' nutrition and clinical characteristics and evaluated the relationship between clinical outcomes and nutrition risk. They demonstrated that 1-unit elevation in NRS scores was related to a more extended hospital stay and a higher risk of mortality in their logistic regression model.

Yadaw et al. [24] devised a useful prediction model of COVID-19 mortality utilizing unbiased computational techniques and detected the most predictive clinical features. Their machine learning framework was mainly based on three clinical features: minimum oxygen saturation throughout patients' medical encounters, age, and type of patient encounter. Their COVID-19 mortality prediction model exhibited a competitive accuracy.

It is a hot research area whether the severity of COVID-19 health outcomes, including death, is associated with long-term exposure to air pollution. But the limitation of COVID-19 data availability and quality hinders in conducting decisive studies in this regard. COVID-19 outcome publicly available data for representative populations are available as area-level counts. Hence, In [25], an ecological regression analysis was studied that precluded controlling for individual-level COVID-19 risk factors.

Zhou et al. [26] exploited the clinical, demographic, and laboratory data, including serial samples for viral RNA detection from the electronic health records from hospitals in China and compared between non-survivors and survivors. They utilized univariable and multivariable logistic regression methods to study the risk factors associated with in-hospital mortality. The potential risk factors of the high SOFA score, older age, and d-dimer greater than 1 µg/mL could help clinicians diagnose patients with poor prognosis at an early stage. In Supplementary Table S2, the relationship between some of the common clinical features of COVID-19 patients with mortality rate is listed.

Although a number of studies have explored the association of mortality with clinical features of COVID-19, those studies did not provide a comprehensive list of list clinical features associated with COVID-19 mortality. In this study, we aimed to determine the association of a wide range of clinical features associated with COVID-19 mortality for the first time.

2. Method

From March 2020 to November 2020, 3008 patients with COVID-19, of which 94.5% (2844 cases) were of Iranian nationality and 5.5% (164 cases) were Afghan nationals, were examined in this experiment. Of these 3008 cases infected with COVID-19, 56% were men, and 44% were women with an age average of 59.3 ± 18.7 years (1-100 years). In Figure 1, the number of patients in a different range of ages and their

mortality numb is illustrated. Of the patients admitted to the hospital during this period, 18.5% required to be admitted to the intensive care unit and the rest to the isolated and normal wards. 387 patients (12.9%) with Covid-19 were in contact with the infected person, and 2621 patients (87.1%) declared any contact with the infected person. About 70.4% of patients referred us personally, and 653 (21.7%) of them conveyed to the hospital by pre-hospital emergency, 199 (6.6%) by private ambulance and 38 (1.3%) by ambulances available in other centres.

Figure 1. The relationship between mortality and age

PCR test was performed for 2822 cases (93.8%), of which 1431 cases (47.6%) were positive, and 1286 cases (42.8%) were negative. PCR test was not performed in 186 patients (6.2%) and was not reported for 104 patients (3.5%). Of the studied patients, 20 patients (0.7%) had a history of the previous infection. Patients admitted to the hospital were associated with symptoms including 32.2% fever, 28% cough, 14% myalgia, 43.3% loss of consciousness, 0.8% loss of sense of smell, 0.5% loss of taste, 0.4% seizures, 4.6% headache, 1.6% dizziness, 0.4% paresis, 0.1% plague, 3.8% chest pain, 3.8% chills, 0.5% sweating, 0.5% dry throat and sore throat, 7.8% weakness and lethargy, 0.2% sputum excretion, 0.2% gastrointestinal bleeding, 2.3% abdominal pain, 5.4% Nausea, 3.8% vomiting, 2.9% diarrhoea and 4.4% anorexia. Other initial symptoms included hemoptysis (in 2 patients), edema, restlessness, delirium, earache, constipation, palpitations, sudden loss of vision, and hematuria (each in one case). Fifty cases (1.7%) were a smoker, and 70 cases (2.3%) were addicted to drugs. 2764 patients underwent CT scan, of which 2277 had symptoms, and 244 did not undergo CT scan. 178 patients (5.9%) needed mechanical ventilation at the beginning of the study, and the others did not. The average ($\pm$ standard deviation) level of oxygen saturation at referral was $89.3\% \pm 7.4\%$ (39%-100%). 37.2% of patients had more than 93% oxygen saturation.

The number of patients' respiration per minute were also measured in such a way that 0.3% (9 patients) did not breathe at all, 194 patients (6.4%) with 10-14 breaths, 1068 patients (35.5%) had 14-18 breaths and 1296 patients (43.1%) showed 18-22 breaths per minute. Indeed, 353 patients (11.8%) had 22-28 breaths, and 88 patients (2.9%) had more than 28 breaths per minute. The average ($\pm$ SD) of patients' body temperature at the time of referral was 37.1 ± 0.7 °C (35-40). 21.8% of patients had a fever at the time of referral.

The average ($\pm$ SD) duration of symptoms until referral was 4.7 ± 13.9 days. In these patients, 1670 patients (55.5%) had risk factors or underlying diseases, so that 104 patients (3.5%) had cancer, 16 patients (0.5%) had liver disease, 588 patients (19.5%) with diabetes, 39 (1.3%) with chronic haematological diseases, 15 (0.5%) with immunodeficiency, 586 patients (19.5%) with cardiovascular diseases, 177 patients (5.9%) with kidney diseases, 108 patients (3.6%) with asthma, 99 patients (3.3%) with chronic lung diseases, 127 patients (4.2%) with neurological diseases, 695 patients (23.1%) with hypertension, 26 patients (0.8%) with CVA and stroke, 8 patients (0.2%) with neurosurgery related problems, 28 patients (0.9%) with hypothyroidism, 43 patients (1.4%) with other neurological diseases, 42 patients (1.3%) with hyperlipidemia, 15 patients (0.4%) with prostate, 43 patients (1.4%) with psychological diseases, 10 patients

(0.3%) with history of veteran chemical warfare and 24 patients (0.7%) had anemia. Among them, 6 cases (0.5%) were pregnant. Out of 177 patients with kidney disease, 77 were on dialysis.

1338 patients (44.5%) had no risk factor and underlying disease. 823 (27.4%) and 567 (18.8%) patients had one and two risk factors, respectively. Three risk factors were observed in 218 (7.2%) and 52 cases (1.7%), respectively. Nine (0.3%) and one patient (0.05%) had five and six risk factors, respectively. Of these patients, 112 (3.7%) were hospitalized, 2523 (83.9%) were discharged, and also 373 (12.4%) died. The average ($\pm$ SD) duration of hospitalization was 6.17 ± 6.3 days (1-87 days), of which 236 patients (7.8%) did not need hospitalization, and 2154 patients (71.6%) required 1-7 days of hospitalization. 376 cases (12.5%) 8-14 days, 137 cases (4.6%) 15-21 days, 59 cases (2%) 22-28 days and 16 cases (0.5%) more than 28 days were hospitalized.

According to these data, the prevalence of COVID-19 infection was high in March 2020 and then had the lowest incidence in May and June, and finally reached its peak in October and was associated with the lowest incidence in November (Figure 2).

Figure 2. Number of patients between March 2020 and November 2020

Local ethical committee of the university approved this research. The patients were informed about this research aims, and written consent was obtained before data collection.

Statistical analysis

Data are presented as the number of patients in a specific category and the mortality rate in each of them. We analysed the features using Matlab 2018b software. To specify differences between the two groups, Wilcoxon Rank-Sum Test 18 and Fisher's exact test 17 were used for continuous and categorical data respectively. $P \leq .05$ sets as the statistical significance.

3. RESULT

The effect of early symptoms on the outcome of patients' deaths

Table 1 shows the effect of different features on the mortality rate. Mortality was not significantly different between men (1684 cases) vs. women (1324 cases). There was a significant difference between mortality and age of patients ($P < 0.001$), infection time ($P < 0.001$), and the hospitalization ward (isolated ward, intensive care unit, normal ward) ($P < 0.001$). Symptoms such as fever, myalgia, dizziness, seizure, abdominal pain, nausea, vomiting, diarrhoea and anorexia were occurred without having mortality related to COVID-19 ($P > 0.05$). There was a significant difference between mortality and headache in patients infected with COVID-19 ($P < 0.011$). Presentation of chest pain was also associated significantly with COVID-19 related mortality ($P < 0.045$). Decreased level of consciousness was also significantly associated with

COVID-19 related mortality ($P < 0.000$). Respiratory distress, oxygen saturation less than 93%, lower respiratory rate and need for mechanical ventilation were associated with COVID-19 related mortality ($P < 0.004$, $P < 0.000$, $P < 0.000$ and $P < 0.000$, respectively).

Opium addiction, smoking status, pregnancy, diabetes mellitus, underlying cancer, liver disease, lung disease, asthma, kidney disease, chronic haematological diseases, other chronic diseases, and receiving immunosuppressive medicines had no association COVID-19 related mortality. Underlying cardiovascular disease, hypertension and neurological diseases were associated with COVID-19 related mortality ($P < 0.023$, $P < 0.003$ and $P < 0.012$, respectively). The presence of CT scan symptoms was significantly related to mortality in COVID-19 cases ($P < 0.000$). There was a significant difference between mortality and having a risk factor for patients with COVID-19 ($P < 0.003$). There was a significant difference between mortality and the number of risk factors in patients with COVID-19 ($P < 0.002$).

Table 1. The effect of some features on the mortality rate

	Number	Deceased	Percent	p- value
sex				
male	1684	216	12.8	0.424
female	1324	157	11.8	
Age category				
14 years and less	12	1	8.3	0.001
15-24	94	3	3.2	
25-34	215	1	0.5	
35-44	373	22	5.9	
45-54	477	30	6.3	
55-64	577	54	9.4	
65-74	541	79	14.6	
75-84	440	106	24.1	
85-94	246	69	28.1	
95 and more	33	8	24.2	
Month (infection – hospitalization)				
March 2020	315	40	12.7	0.001
April 2020	283	52	18.4	
May 2020	205	25	12.2	
June 2020	209	23	11	
July 2020	328	43	12.8	
August 2020	366	45	12.3	
September 2020	449	60	13.4	
October 2020	493	65	13.2	
November 2020	493	20	5.5	
Inpatient department				
isolated	1554	90	5.8	0.001
Special	555	248	44.7	
Normal	899	35	3.9	
Symptoms				
Fever	969	109	11.2	0.187
Myalgia	422	40	9.4	0.051
Seizures	13	0	0	0.994
Dizziness	42	4	9.5	0.580
Abdominal pain	68	6	8.8	0.365
Nausea	163	20	12.2	0.954
Vomiting	115	19	16.5	0.174
Diarrhea	87	9	10.3	0.552
Anorexia	113	15	13.2	0.683
Smoking	50	4	8	0.346
Addiction	70	7	10	0.539
Cancer	104	19	18.2	0.067
Liver disease	16	2	12.5	0.990
Diabetes	588	83	14.1	0.160
Chronic blood disease	39	5	12.8	0.936

Receiving immunosuppressive drugs	14	1	7.1	0.556	
Pregnancy	373	0	0	0.994	
Other chronic diseases	239	34	14.2	0.373	
Kidney disease	177	24	13.5	0.630	
Asthma	108	20	18.5	0.052	
Lung diseases	99	18	18.1	0.078	
Cough	843	87	10.3	0.031	
Respiratory distress	1301	187	14.3	0.004	
Decreased level of consciousness	198	57	28.7	0.000	
Headache	137	7	5.1	0.011	
Chest pain	114	7	6.1	0.045	
Having symptoms on CT scan	2277	313	13.7	0.000	
Need for mechanical ventilation	178	90	50.5	0.000	
Oxygen saturation	More than 93%	Less than 93%	More than 93%	Less than 93%	0.000
	1120	1888	53	320	
Respiratory rate	644	95	14.7	0.000	
Cardiovascular disease	586	89	15.1	0.023	
Neurological diseases	127	25	19.6	0.012	
Blood pressure	695	109	15.6	0.003	
Having a risk factor	1670	234	14	0.003	
Having multiple risk factors	847	139	16.4	0.002	

4. Discussion

The main findings of our study are the significant association between mortality of COVID-19 and old age, headache, chest pain, respiratory distress, low respiratory rate, oxygen saturation less than 93%, need to a mechanical ventilator, having symptoms on CT, hospitalization in wards, and time to infection. Besides, history of hypertension, neurological disorders, cardiovascular diseases, having a risk factor or multiple risk factors were associated with the COVID-19 mortality. Interestingly, there was no significant association between mortality and gender, fever, myalgia, dizziness, seizure, abdominal pain, nausea, vomiting, diarrhoea, and anorexia. We observed no association regarding COVID-19 related mortality and headache, chest pain, having symptoms on CT, hospitalization in wards and time to infection. Indeed, history of neurological disorders, having a risk factor or multiple risk factors, fever, myalgia, dizziness, seizure, abdominal pain, nausea, vomiting, diarrhoea and anorexia with COVID-19 related mortality were not found in other investigations.

The significant association between age and COVID-19 related mortality in our study is in line with previous studies conducted by Zhou et al. [26], Pettit et al. [27], Chen et al. [28], Iftime et al. [29], and in contrast to De Smet et al. [30], Sun et al. [31] and Li et al. [19]. Immune impairment and the enhanced possibility of developing cardiovascular and respiratory diseases would be the joint linkage between old age and COVID-19 related mortality [32]. The observed association between the underlying cardiovascular diseases and COVID-19 related mortality in our study was in line with Chen et al. [33], Soares et al. [34] and Ruan et al. [35], but was contrary to Iftimie et al. [36], Li et al. [37] and Ciardullo et al. [38] findings. We found underlying high blood pressure to be associated with COVID-19 mortality, which is in line with Li et al. [37] finding and is in contrast with Rawl et al. [39], Pei et al. [40], Sun et al. [31] and Ciardullo et al. [38] findings. Hospitalization in wards was associated with COVID-19 related mortality, parallel with Chen et al. [41] findings, who found a relationship between ICU admission and mortality. The association between the need for mechanical ventilation and COVID-19 related mortality is in line with Chen et al. [41] and Zhou et al. [26] findings. The association between low oxygen saturation and low respiratory rate with mortality was in contrast with Sun et al. [31] findings.

In our previous study, anorexia, dry cough, anosmia and history of cancer were associated with COVID-19 related mortality [32], but in this study, we observed no relationship between mortality of COVID-19 and

cancer, that may be due to different population of the study; two other provinces from one country. Anorexia showed a significant positive relationship with COVID-19 related mortality by Rawl et al. [39]. Regarding comorbidities, finding no significant association between cancer and COVID-19 related mortality is in line with Lee et al. [42] findings but is in contrast with Iftimie et al. [29], Mehta et al. [43], Dai et al. [44], Westblade et al. [45], Melo et al. [46], and Rthrich et al. [47] findings. Different demographic features could explain this discrepancy. Finding no association between gender and COVID-19 related mortality is the same as Ruan et al. [35], Mehta et al. [43], Sun et al. [31]. Absence of association between fever and COVID-19 related mortality in our study is the same as our previous research [32], but it contrasts with the findings of Iftime et al. [29]. Myalgia, diarrhoea, nausea and vomiting were not predictors of mortality in our cohort, which contrast with Zhou et al. [26] findings.

The most important strength of this research is investigating impact of some new features on mortality rate of COVID-19 patients. Another important strength of this research is the large amount of the data used. However, there are some weaknesses. The patients are from a specific region. It is mentioned [48] that factors associated with mortality may differ in various regions. In addition, detailed clinical data on cardiovascular parameters were not available. Future research is needed investigating mortality of COVID-19 in heart disease patients.

5. Conclusion

In this research, we investigated the effect of some of the risk factors and symptoms of COVID-19 mortality rate for the first time. Our results show a significant association between mortality and risk factors like old age, headache, chest pain, respiratory distress, low respiratory rate, oxygen saturation less than 93%, need to a mechanical ventilator, having symptoms on CT, hospitalization in wards, time to infection, history of hypertension, neurological disorders, cardiovascular diseases, and having a risk factor or multiple risk factors. In contrast, there is no significant association between mortality and gender, fever, myalgia, dizziness, seizure, abdominal pain, nausea, vomiting, diarrhoea and anorexia. More studies are needed to confirm these findings. As future work, we will investigate the mortality rate of COVID-19 heart disease patients.

Ethical approval

The study was approved by the Omid Hospital Ethics Committee.

Data availability

The data that support the findings of this study are available on request from the corresponding author.

References

1. Zhou, P., et al., *A pneumonia outbreak associated with a new coronavirus of probable bat origin*. Nature, 2020. **579**(7798): p. 270-273.
2. Goldberg, D., *Critical reviews in clinical laboratory sciences*. Critical reviews in clinical laboratory sciences, 2010. **47**(1): p. 1-4.
3. Sharifrazi, D., et al., *Fusion of convolution neural network, support vector machine and Sobel filter for accurate detection of COVID-19 patients using X-ray images*. Biomedical Signal Processing and Control, 2021. **68**: p. 102622.
4. Alizadehsani, R., et al., *Uncertainty-Aware Semi-supervised Method using Large Unlabelled and Limited Labeled COVID-19 Data*. arXiv preprint arXiv:2102.06388, 2021.
5. Wang, D., et al., *Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China*. Jama, 2020. **323**(11): p. 1061-1069.
6. Lippi, G. and M. Plebani, *The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks*. Clinical Chemistry and Laboratory Medicine (CCLM), 2020. **58**(7): p. 1063-1069.
7. Bhargava, A., et al., *Predictors for Severe COVID-19 Infection*. Clinical Infectious Diseases, 2020. **71**(8): p. 1962-1968.
8. Hamming, I., et al., *Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis*. The Journal of Pathology, 2004. **203**(2): p. 631-637.

9. Renu, K., P.L. Prasanna, and A. Valsala Gopalakrishnan, *Coronaviruses pathogenesis, comorbidities and multi-organ damage – A review*. Life Sciences, 2020. **255**: p. 117839.
10. Lippi, G. and E.J. Favaloro, *D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis*. Thrombosis and haemostasis, 2020. **120**(5): p. 876-878.
11. Whitelaw, S., et al., *Applications of digital technology in COVID-19 pandemic planning and response*. The Lancet Digital Health, 2020. **2**(8): p. e435-e440.
12. Asgharnezhad, H., et al., *Objective Evaluation of Deep Uncertainty Predictions for COVID-19 Detection*. arXiv preprint arXiv:2012.11840, 2020.
13. Society of Critical Care Medicine. US ICU availability for COVID-19. <https://sccm.org/getattachment/Blog/March-2020/United-States-Resource-Availability-for-COVID-19/United-States-Resource-Availability-for-COVID-19.pdf?lang=en-U> (accessed December 22, 2020).
14. News National. Singapore's coronavirus temperature screening and tracking are leading the way. <https://thenewdaily.com.au/news/national/2020/03/19/singapore-coronavirus-temperature-scans/> (accessed December 22, 2020).
15. McCall, B., *COVID-19 and artificial intelligence: protecting health-care workers and curbing the spread*. The Lancet Digital Health, 2020. **2**(4): p. e166-e167.
16. Naudé, W., *Artificial intelligence vs COVID-19: limitations, constraints and pitfalls*. AI & SOCIETY, 2020. **35**(3): p. 761-765.
17. Shi, Q., et al., *Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study*. Diabetes Care, 2020. **43**(7): p. 1382.
18. Ji, Y., et al., *Potential association between COVID-19 mortality and health-care resource availability*. The Lancet Global Health, 2020. **8**(4): p. e480.
19. Li, X., et al., *Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan*. Journal of Allergy and Clinical Immunology, 2020. **146**(1): p. 110-118.
20. Moghaddam, A., et al., *Selenium Deficiency Is Associated with Mortality Risk from COVID-19*. Nutrients, 2020. **12**(7): p. 2098.
21. Qin, J.-J., et al., *Redefining Cardiac Biomarkers in Predicting Mortality of Inpatients With COVID-19 Hypertension*, 2020. **76**(4): p. 1104-1112.
22. Zhang, X.-J., et al., *In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19*. Cell Metabolism, 2020. **32**(2): p. 176-187.e4.
23. Zhao, X., et al., *Evaluation of Nutrition Risk and Its Association With Mortality Risk in Severely and Critically Ill COVID-19 Patients*. Journal of Parenteral and Enteral Nutrition, 2021. **45**(1): p. 32-42.
24. Yadaw, A.S., et al., *Clinical features of COVID-19 mortality: development and validation of a clinical prediction model*. The Lancet Digital Health, 2020. **2**(10): p. e516-e525.
25. Wu, X., et al., *Air pollution and COVID-19 mortality in the United States: Strengths and limitations of an ecological regression analysis*. Science Advances, 2020. **6**(45): p. eabd4049.
26. Zhou, F., et al., *Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study*. The Lancet, 2020. **395**(10229): p. 1054-1062.
27. Pettit, N.N., et al., *Obesity is Associated with Increased Risk for Mortality Among Hospitalized Patients with COVID-19*. Obesity, 2020. **28**(10): p. 1806-1810.
28. Chen, R., et al., *Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China*. Chest, 2020. **158**(1): p. 97-105.
29. Iftimie, S., et al., *Risk factors associated with mortality in hospitalized patients with SARS-CoV-2 infection. A prospective, longitudinal, unicenter study in Reus, Spain*. PloS one, 2020. **15**(9): p. e0234452.
30. De Smet, R., et al., *Frailty and Mortality in Hospitalized Older Adults With COVID-19: Retrospective Observational Study*. Journal of the American Medical Directors Association, 2020. **21**(7): p. 928-932.e1.
31. Sun, H., et al., *Risk Factors for Mortality in 244 Older Adults With COVID-19 in Wuhan, China: A Retrospective Study*. Journal of the American Geriatrics Society, 2020. **68**(6): p. E19-E23.
32. Alizadehsani, R., et al., *Risk Factors Prediction, Clinical Outcomes, and Mortality of COVID-19 Patients*. medRxiv, 2020.
33. Chen, R., et al., *Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China*. Chest, 2020.
34. Soares, R.d.C.M., L.R. Mattos, and L.M. Raposo, *Risk factors for hospitalization and mortality due to COVID-19 in Espírito Santo State, Brazil*. The American journal of tropical medicine and hygiene, 2020. **103**(3): p. 1184-1190.

35. Ruan, Q., et al., *Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China*. Intensive Care Medicine, 2020. **46**(5): p. 846-848.
36. Iftime, S., et al., *Risk factors associated with mortality in hospitalized patients with SARS-CoV-2 infection. A prospective, longitudinal, unicenter study in Reus, Spain*. bioRxiv, 2020.
37. Li, J., et al., *Defining heart disease risk for death in COVID-19 infection*. QJM: An International Journal of Medicine, 2020. **113**(12): p. 876-882.
38. Ciardullo, S., et al., *Impact of diabetes on COVID-19-related in-hospital mortality: a retrospective study from Northern Italy*. Journal of Endocrinological Investigation, 2020.
39. Rawle, M.J., D.L. Bertfield, and S.E. Brill, *Atypical presentations of COVID-19 in care home residents presenting to secondary care: A UK single centre study*. AGING MEDICINE, 2020. **3**(4): p. 237-244.
40. Pei, G., et al., *Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia*. Journal of the American Society of Nephrology, 2020. **31**(6): p. 1157.
41. Chen, J., et al., *Distinct Clinical Characteristics and Risk Factors for Mortality in Female Inpatients With Coronavirus Disease 2019 (COVID-19): A Sex-stratified, Large-scale Cohort Study in Wuhan, China*. Clinical Infectious Diseases, 2020. **71**(12): p. 3188-3195.
42. Lee, L.Y.W., et al., *COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study*. The Lancet Oncology, 2020. **21**(10): p. 1309-1316.
43. Mehta, V., et al., *Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System*. Cancer Discovery, 2020. **10**(7): p. 935.
44. Dai, M., et al., *Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak*. Cancer Discovery, 2020. **10**(6): p. 783.
45. Westblade, L.F., et al., *SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19*. Cancer Cell, 2020. **38**(5): p. 661-671.e2.
46. de Melo, A.C., et al., *Cancer inpatients with COVID-19: A report from the Brazilian National Cancer Institute*. PloS one, 2020. **15**(10): p. e0241261.
47. Rüthrich, M.M., et al., *COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registry*. Annals of Hematology, 2021. **100**(2): p. 383-393.
48. Alizadehsani, R., et al., *Coronary Artery Disease Detection Using Artificial Intelligence Techniques: A Survey of Trends, Geographical Differences and Diagnostic Features 1991-2020*. Computers in Biology and Medicine, 2020: p. 104095.
49. Reddy, R.K., et al., *The effect of smoking on COVID-19 severity: A systematic review and meta-analysis*. Journal of Medical Virology, 2021. **93**(2): p. 1045-1056.
50. Magfira, N. and H. Helda, *Correlation between adult tobacco smoking prevalence and mortality of Coronavirus Disease-19 across the world*. medRxiv, 2020.
51. Mendy, A., et al., *Factors Associated with Hospitalization and Disease Severity in a Racially and Ethnically Diverse Population of COVID-19 Patients*. medRxiv, 2020: p. 2020.06.25.20137323.
52. Poloni, T.E., et al., *Prevalence and prognostic value of Delirium as the initial presentation of COVID-19 in the elderly with dementia: An Italian retrospective study*. EClinicalMedicine, 2020. **26**: p. 100490.
53. Hue, S., et al., *Uncontrolled innate and impaired adaptive immune responses in patients with COVID-19 acute respiratory distress syndrome*. American journal of respiratory and critical care medicine, 2020. **202**(11): p. 1509-1519.
54. Chen, Q., Z. Zheng, and C. Zhang, *Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou*.
55. Zhang, J.-j., et al., *Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China*. Allergy, 2020. **75**(7): p. 1730-1741.
56. Homayounieh, F., et al., *Clinical and imaging features predict mortality in COVID-19 infection in Iran*. Plos one, 2020. **15**(9): p. e0239519.
57. Sorouri, M., et al., *Clinical characteristics, outcomes, and risk factors for mortality in hospitalized patients with COVID-19 and cancer history: a propensity score-matched study*. Infectious Agents and Cancer, 2020. **15**(1): p. 74.

Table S2. Some of the typical clinical characteristics of COVID-19 patients with mortality

Ref No.	The population of Samples/No. Of Studies	Country	Feature name	P- Value
Zhou et al. [26]	171	China	Acute cardiac injury	<0.0001
			Acute kidney injury	<0.0001
			Respiratory failure	<0.0001
			Invasive/Non-invasive mechanical ventilation	<0.0001
Pettit et al. [27]	238	USA	Age	<0.0005
Li et al. [19]	269	China	Age, > 65 y vs <65 y	0.021
Chen et al. [28]	1,590	China	Age (≥75 vs <65)	< 0.001
De Smet et al. [30]	81	Belgium	Age	0.03
Iftime et al. [29]	188	Spain	Age	<0.001
			Fever	0.046
Ruan et al. [35]	150	China	Gender	0.43
Reddy et al. [49]	47 Studies	Different nationalities	Smokers	<□0.0001
Magfira et al. [50]	Data from 74 countries	Different nationalities	Male Smoking	0.16
Dai et al. [44]	641	China	Cancer	0.03
Mehta et al. [43]	218	United States	Cancer	< 2.2e-16
			Gender	0.6
Melo et al. [46]	60	Brazil	metastatic cancer	<0.001
Lee et al. [42]	123	The U.K.	Lung Cancer	0.29
			Prostate Cancer	0.82
			Leukaemia	0.023
Rüthrich et al. [47]	435	U.K.	Cancer	< 0.001
Westblade et al. [45]	2,914	United States	Hematologic malignancy	0.006
Chen et al. [41]	3309	China	Acute kidney injury	0.033
			Acute liver injury	<0.0001
			Acute respiratory distress syndrome	<0.0001
			Septic shock	<0.0001
			Coagulation disorder	<0.0001
			Oxygen treatment	0.390
			Mechanical ventilation	<0.0001
			ICU admission	<0.0001
			Systemic glucocorticoids	<0.0001
Soares et al. [34]	10,713	Brazil	Kidney diseases	< 0.001
			Cardiovascular diseases	0.001
			Diabetes	0.003
			Obesity	<0.001
			Smoking	<0.001
			Race(Asian/indigenous/unknown)	<0.001
			Shortness of breath	<0.001
			Sore throat	<0.001
Pei et al. [40]	198	China	Acute kidney injury	<0.001
			Current pregnancy	<.0001
			History of solid organ transplant	0.2597
			History of chronic kidney disease	<0.0001
			History of cardiovascular disease	<0.0001
			History of hypertension	0.2716
Mendy et al. [51]	689	USA	smoker	0.659
			Diabetes	0.193
			Obesity	0.881
			Chronic kidney disease	0.001
			Anemia	0.040
			Thrombocytopenia	<0.001
			Coagulation defect	<0.001
			Race/ethnicity (Non-Hispanic Black)	0.012
Li et al. [37]	596	China	Hypertension	0.001
			Coronary heart disease	0.054
			Malignancy	0.120

Ciardullo et al. [38]	373	Italy	chronic obstructive pulmonary disease	0.084
			Cardiovascular diseases	0.348
			Hypertension	0.137
			Diabetes	0.253
Polon et al. [52]	57	Italy	Dementia	0.002
Sun et al. [31]	244	China	SpO2, %	0.565
			Respiratory rate, breaths/min	0.181
			Consciousness disorders (disorders vs clear)	0.827
			Hypertension	0.744
			Age	0.037
			Gender	0.270
Hue et al. [53]	74	France	Acute Respiratory Distress Syndrome (ARDS) severity	0.007
Chen et al. [54]	145	China	anorexia	0.01
Zhang et al. [55]	139	China	anorexia	0.588
Homayounieh. [56]	90	Iran	headache	0.3
			chest pain	0.2
			lower lung area	0.04
Sorouri et al. [57]	172		fever	0.412
			Cough	0.398
			Chills	0.610
			myalgia	0.990
			nausea	0.135
			diarrhea	0.491
			Sore throat	0.990
			Fatigue	0.786
			Anorexia	0.076
			Chest pain	0.304
			dyspnea	0.013
Rawle et al. [39]	134	U.K.	Anorexia	0.028
			Respiratory disease	0.609
			Cardiac disease	0.333
			Diabetes mellitus	0.787
			Hypertension	0.728